
apr pm et
summari compani make market comprehens line product servic treat
price-to-earnings oper ep
risk assess reflect compani highli
competit industri character technolog
innov new market entrant rang
start-up establish medic product develop
compani must consist enhanc product
develop new one maintain competit stand
howev demand product immun econom
cycl tend exhibit stabl long-term unit price
jul ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
apr stock trade
expect sale grow
billion follow rise see
continu robust low-teen growth
transcathet heart valv sale
billion continu strong uptak
sapien valv europ well
sapien xt japan driven robust procedur
growth believ issu franc
limit transcathet aortic valv
replac tavr procedur set
resolv aid sale growth
howev note increas competit
corevalv tavr two competitor launch
europ surgic heart valv therapi
expect sale million
expect sale million
geograph expans increas demand
core hemodynam monitor product
see oper margin
see ep aid lower tax
rate
think share -- trade
slightli peer -- attract
valu although see ew recent robust
sale growth moder think premium
warrant expect ew maintain
lead market share well
focu favor pipelin product
promis see multipl long-term
growth opportun recent approv
sapien europ well
sapien xt japan like help
approv sapien ultra
mitral opportun larg potenti new
commerci launch sever year away
howev competit intens includ
corevalv launch new
competitor europ
risk recommend target price
includ market share loss key product
categori inabl success
commerci product pipelin
target price reflect
multipl ep estim
peer faster growth within
five-year rang
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview corp develop manufactur market product
technolog design treat advanc stage cardiovascular diseas
ew total heart valv therapi line consist surgic heart valv cardiac surgeri system
core surgic heart valv product line carpentier-edward perimount pericardi valv
includ line perimount magna valv recent addit perimount product line includ
perimount magna eas aortic mitral valv durabl tissu valv extend
use thermafix xenologix tissu treatment process ew also sell porcin valv
current phase stentless tissu valv ew also global leader heart valv repair
therapi includ annuloplasti ring system introduc next gener
cardiac surgeri system busi complement heart valv line includ cannula
use cardiac surgeri venou drainag aortic perfus vent cardioplegia deliveri
embol-x intra-aort filtrat system captur emboli releas applic releas
aortic cross clamp on-pump cardiac surgeri minim invas surgeri product includ
port-access product proprietari endocpb system minim invas heart valv
surgeri compris soft tissu retractor venou arteri cannula aortic occlus vent
coronari sinu cathet reusabl instrument perform port-access cardiac valv procedur
catheter-bas approach oppos open surgic techniqu aortic valv replac
develop sapien tavr deliv use retroflex deliveri system transfemor tf
leg approach ascendra deliveri system transap ta rib
approach minim access beat heart procedur sapien valv sold europ
intern market ew next-gener sapien xt deliv use lower
profil novaflex deliveri system tf approach deliveri system ta approach
avail sale europ intern market
critic care segment sell hemodynam monitor system use measur patient
heart function surgic intens care set product often deploy
open heart major vascular major abdomin neurolog orthoped surgic
procedur ew also sell dispos pressur monitor devic product line enabl closed-loop
arteri blood sampl protect patient clinician infect product perform
hemofiltr vascular product treat peripher vascular diseas includ balloon-tip
catheter-bas product surgic clip insert angioscopi equip implant graft
corpor strategi believ key growth within medic devic industri maintain
product research develop program edward invest signific portion sale
effort spend total million sale million million
respect expect compani continu invest heavili
 ew invest develop transcathet aortic valv tav replac repair
technolog design treat heart valv diseas use catheter-bas approach oppos open
surgic techniqu ew believ sale catheter-bas valv repair replac product could
exceed billion next decad ew also develop product area transcathet mitral
valv repair minim invas hemodynam monitor system balloon-expand
self-expand non-coronari stent new treatment peripher vascular diseas
gener counsel
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
ew slightli overvalu
neutral sinc april technic indic ew
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
posit continu view mani product
categori histor recession-resist
expect continu grow growth
procedur rate area view
non-elect cardiac rhythm
manag intervent cardiolog
orthoped steadili improv
see continu recoveri
medic devic tax requir
healthcar reform law went effect
januari temporarili suspend
januari
congress pass stopgap measur includ
suspend medic devic tax anoth
two year tax
slate becom effect januari
decemb congress pass tax cut
job act includ repeal
individu mandat compon
afford act requir
peopl health insur pay fine
effect januari believ repeal
individu mandat result fewer
insur peopl neg impact
equip sub-industri fewer insur
patient would like lead fewer procedur
anticip hospit
largest buyer medic equip would also
advers impact could
pressur sub-industri
expect revenu rise constant
currenc mid- upper-singl digit pace
aid new product expans emerg
market case acquisit
still expect extend replac cycl
 hospit area price
pressur lower demand certain product
categori affect sale growth also think
 hospit becom cautiou
regard capit budget amid shift
base index
five-year market price perform apr
procedur inpati
includ increas global demand
qualiti health care age popul
rise outlay lead steadi flow
new diagnost therapeut product
 health equip
 composit index year
date april health
declin composit index
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
amid increas competit moder sale growth keep
target peer ep estim
set ep estim sale rose transcathet heart valv
sale sale franc remain limit ew negoti french polici
limit procedur ep vs ahead estim
ew maintain sale guidanc ep
analyst research note compani news
et cfra maintain buy opinion share edward
lifesci corpor ew maintain target
above-p next ep estim
multipl near middl ew five-year rang ep
vs higher estim rais ep
sale increas million
transcathet heart valv therapi thvt total sale
due difficult comparison prior-year period result
stock germani surgic heart valv therapi shvt
declin shvt primarili relat convers consign
inventori model surgic valv us result increas
sale reserv european sale focal point fell howev sale
would grown adjust germani stock foreign exchang
effect despit difficult quarter sale continu expect robust
adopt thvt global /kevin huang
et cfra reiter buy opinion share edward
lifesci corpor ew rais target
above-p ep estim
high-end five-year rang ep vs
ahead view set sale rose
transcathet heart valv therapi double-digit growth
region europ sale aid recoveri franc limit
number procedur last year see robust adopt transcathet
aortic valv replac tavr aid strong intern sale
tavr center /jeffrey loo cfa
et cfra keep buy opinion share edward lifesci
corpor ew lower target
forward ep estim within ew rang
ep vs estim lower
ep estim sale rose forecast
slowdown transcathet aortic valv replac tavr procedur
earlier year sizeabl slowdown believ
ew fundament remain intact still see robust growth tavr procedur
et cfra keep buy opinion share edward lifesci
ew rais target peer
next ep estim faster growth ep
vs ahead estim rais ep
estim sale rose
transcathet heart valv therapi sale rose robust therapi adopt
across geographi sale believ ew continu
expand market share expect new product includ ultra
centera launch europ later year help drive sale growth
lifesci corpor ew rais target
above-p next ep estim faster
growth sale includ germani stock sale rose
transcathet heart valv therapi w/o germani german client
stock due potenti suppli interrupt litig boston
scientif ep vs estim rais
ep estim ew narrow
sale guidanc rais ep
/jeffrey loo cfa
et capit iq lift opinion share edward
lifesci buy hold ew share sharpli
see buy opportun expect ew maintain lead market share
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim ew earn
usd quarter fiscal year ew
announc earn per share usd repres
total revenu estim fiscal year
analyst estim ew earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut standard
 poor malaysia sdn bhd cfra malaysia certain research distribut
cfra uk limit cfra uk cfra uk cfra malaysia wholly-own
subsidiari cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
